Invivyd, Inc. (f/k/a Adagio Therapeutics Inc.)

Ticker: IVVD

Class Period Start: 11/29/2021

Class Period End: 12/14/2021

Registration Deadline: 04/04/2023

A securities class action has been filed in the USDC – D. Mass. against Invivyd, Inc. (IVVD) (f/k/a Adagio Therapeutics, Inc.) on behalf of all purchasers of Adagio common stock between November 29, 2021 through December 14, 2021.

Invivyd formed in June 2020, during some of the worst days of the pandemic, to develop drugs for the treatment and prevention of COVID-19 and future coronavirus outbreaks. During the Class Period, Invivyd was focused on developing ADG20, an investigational monoclonal antibody treatment for COVID-19. In September 2022, Adagio announced that it was changing its corporate name to Invivyd.

The Complaint alleges that defendants throughout the Class Period failed to disclose that:

  • the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron;
  • that defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and
  • ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

    On the press release issued by Invivyd, the price of the Company shares declined by nearly 80%, damaging investors.


If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.



Please Note

Neither the submission to nor the receipt of information by Lowey Dannenberg or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* Indicates a required field.

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.